Senti Biosciences

Edit info

Founded: 2016

Location: South SF, CA

Employee range: 50 - 200

Clinical stage: Clin0

Therapy area: AML, MDS, other blood cancers

Drug types: ONC, OPH, NEU, HEP

Lead product: SENTI-202

Funding: $105M Jan 2021; $53M A Feb 2018

Investors: Bayer

sentibio.com

linkedin.com

job board

Drug notes:

SENTI-301A Clin0 hepatocellular carcinoma, solid tumors; SENTI-401 RD colorectal cancer, solid tumors; undisclosed programs RD solid tumors; 3 programs RD ocular, CNS & liver conditions; 3 programs RD regenerative medicine

About:

Senti Biosciences is outsmarting complex diseases by developing intelligent medicines using synthetic biology. Senti Bio designs and optimizes gene circuits, created from novel and proprietary combinations of DNA sequences, to reprogram cells. The gene circuits use biological logic to sense inputs, compute decisions and respond to their cellular environments. Senti Bio is using their Design-Build-Test-Learn development engine to make therapeutic gene circuits that can be engineered into product candidates. Senti Bio’s current focus is on advancing a broad pipeline of gene circuit-enabled products including CAR-NK cells for oncology, gene therapies for tissue-targets and cell therapies for regenerative medicines.